🟢 Protara Therapeutics is trading 9.40% up in pre-market

Protara Therapeutics is trading at $2.63, up +9.40% in pre-market, with no clear catalyst identified.

• On October 15, the company announced enrollment completion for the 24-patient Phase 2b portion of its THRIVE-3 trial; interim results are expected in Q4 2026.
• Cantor Fitzgerald reiterated its Overweight rating, but reporting did not link the action to the pre-market move.
• Broader index moves are mixed and do not establish a cause for the gain.